APOBEC3诱导的耐药突变在抗逆转录病毒治疗管理中应如何考虑?
结果显示,尽管存在APOBEC3诱导突变,换用PAIT后病毒学抑制得以维持,病毒学失败与APOBEC3诱导突变无关。提示在抗逆转录病毒治疗管理中不应考虑APOBEC3诱导突变。
要点
- 细胞相关HIV-DNA耐药检测中APOBEC3诱导突变不应影响治疗决策。
- 换用潜在受APOBEC3诱导突变影响的方案后病毒学抑制可维持。
- 病毒学失败与APOBEC3诱导突变无关,多与依从性差或治疗中断有关。
核心结论
- 尽管细胞相关HIV-DNA耐药基因型检测中存在APOBEC3诱导突变,换用PAIT后病毒学抑制仍得以维持,病毒学失败与APOBEC3诱导突变无关,提示APOBEC3诱导突变不应在抗逆转录病毒治疗管理中考虑。
主要发现
- 在引入PAIT时,除一人外所有个体均实现病毒学抑制。
- 4例发生病毒学失败,均与ART依从性差或ART中断相关。
- 其中2例更换ART:1例因制剂适配,另1例因整合酶出现N155H耐药突变,后者换用含PI的ART后获得病毒学抑制。
- 另2例未更换ART即恢复病毒学抑制。
关键数值与推荐
- 病毒学失败定义为换用PAIT后至少间隔1个月连续两次血浆病毒载量>50 c/mL。
临床怎么用
- 临床管理中不应因细胞相关HIV-DNA耐药检测存在APOBEC3诱导突变而调整ART方案。
- 对于接受PAIT的患者,应关注依从性和治疗中断等导致病毒学失败的因素。
局限性
- 样本量较小(38人,42种PAIT方案)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combined antiretroviral therapy (ART) management guided by the cell-associated HIV-DNA genotypic resistance test (GRT) is not standardized, and its interpretation may be difficult in the presence of APOBEC3-induced mutations at drug resistance-associated positions (APOMut). Our objective was to evaluate the virologic outcome of people living with HIV (PLWH) with HIV-DNA provirus carrying APOMuts when switched to or receiving an ART regimen that would theoretically be significantly impacted by those APOMut (potential APOMut-impacted treatment, PAIT). METHODS: PLWH under PAIT and with a cell-associated HIV-DNA GRT containing APOMut between April 2010 and December 2023 were included. Treatment failure was defined as two consecutive plasma viral load values >50 c/mL at least 1 month apart after the switch to PAIT. RESULTS: We studied 38 PLWH who received 42 distinct PAIT lines. At the time of PAIT introduction, all individuals except one were virally suppressed. Virologic failure occurred in four PLWH; all of these cases were related to either poor ART adherence or ART interruption. Two of them switch to another ART: one for galenic adaptation, and the other due to the emergence of the N155H resistance mutation in integrase. For this individual, virologic suppression was obtained with a PI-containing ART. The two others resumed virologic suppression without any ART switch. CONCLUSIONS: Despite the presence of APOMut in cell-associated HIV-DNA GRTs, virologic suppression was maintained in PLWH switching to PAIT. Virologic failures were unrelated to the presence of APOMut. These results suggest that APOMuts should not be considered in the management of ART.
引用
- Gilbert M, Ferré VM, Guilbaud R, et al. How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy? J Antimicrob Chemother. 2025. PMID: 41016855. doi:10.1093/jac/dkaf353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。